Long COVID Drug BC007 Gets a Second Chance with New Biotech Firm APTA Therapeutics
After a disappointing Phase 2 trial led to the insolvency of Berlin Cures, the future of BC007 – a potential treatment targeting the root causes of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID – looked bleak. Now, a new biotech startup, APTA Therapeutics, led by former Berlin Cures CEO Oliver von Stein, has acquired the rights to the drug, now known as Rovunaptabin, and is forging ahead with further research.
The Initial Promise and Setback of BC007
BC007, or Rovunaptabin, is designed to neutralize misdirected autoantibodies that target G protein-coupled receptors in the body. These autoantibodies are believed to play a role in the development of Long COVID and ME/CFS, particularly the debilitating fatigue experienced by many patients. Initial case studies in 2021 showed promising results, suggesting significant benefits for patients with post-COVID syndrome (PCS).
Yet, the Phase 2 BLOC trial in 2024 failed to demonstrate superiority over a placebo. This outcome proved fatal for Berlin Cures, as it made securing further investment impossible. The trial’s design has since been questioned, with some experts suggesting it was flawed.
A New Hope: APTA Therapeutics and Continued Research
APTA Therapeutics’ acquisition of Rovunaptabin signals a renewed commitment to exploring its potential. Von Stein believes the drug still holds promise as an effective treatment for post-viral illnesses, including Long COVID, ME/CFS, and even cardiovascular diseases. The company is currently focused on further developing Rovunaptabin with the goal of initiating future clinical trials and ultimately bringing it to market.
Interestingly, research at Erlangen University Hospital, initially focused on glaucoma, has also shown positive results with Rovunaptabin. Scientists observed improvements in Long COVID symptoms in a study of 30 selected patients with PCS who exhibited specific autoantibodies against G protein-coupled receptors. This investigator-initiated Phase IIa clinical study, published in eClinicalMedicine, suggests that targeting these autoantibodies could be a viable therapeutic strategy.
Understanding Autoantibodies and Their Role in Long COVID
The core principle behind BC007/Rovunaptabin’s mechanism lies in neutralizing pathogenic autoantibodies. These antibodies, while normally part of the immune system’s defense, can sometimes mistakenly attack the body’s own tissues. In the context of Long COVID, they are thought to contribute to the persistent symptoms experienced by many patients.
Research indicates that not all Long COVID patients have these autoantibodies, suggesting that Rovunaptabin may be most effective for a specific subset of individuals. Identifying these patients through diagnostic testing will be crucial for successful clinical trials.
Lessons Learned from the First Trial
The failure of the initial Phase 2 trial highlighted the importance of careful study design. According to Von Stein, the BLOC trial was “not an optimum study in design.” Future research will aim to address these shortcomings, potentially by focusing on patients with detectable autoantibodies and employing more sensitive outcome measures.
Frequently Asked Questions (FAQ)
- What is Rovunaptabin (BC007)? Rovunaptabin is an aptamer designed to neutralize autoantibodies that may contribute to Long COVID, ME/CFS, and other conditions.
- Why did Berlin Cures proceed insolvent? The company’s Phase 2 trial of BC007 failed to show a significant benefit over placebo, leading to a loss of investor confidence, and insolvency.
- What is APTA Therapeutics planning to do? APTA Therapeutics is continuing the development of Rovunaptabin, aiming to conduct further research and clinical trials.
- Is this treatment suitable for all Long COVID patients? Current research suggests that Rovunaptabin may be most effective for patients with specific autoantibodies.
Did you know? Aptamers, like Rovunaptabin, are synthetic molecules that can bind to specific targets with high affinity, offering a potential alternative to traditional antibody-based therapies.
Stay informed about the latest developments in Long COVID research. Explore other articles on our site for more insights and updates.
